Targeted Silencing of NRF2 by rituximab-conjugated nanoparticles increases the sensitivity of chronic lymphoblastic leukemia cells to Cyclophosphamide

BACKGROUND: Targeting influential factors in resistance to chemotherapy is one way to increase the effectiveness of chemotherapeutics. The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway overexpresses in chronic lymphocytic leukemia (CLL) cells and appears to have a significant part in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Khodakarami, Atefeh, Kashani, Mahsa Afsari, Nazer, Atefeh, Kheshti, Armin Mahmoudsalehi, Rashidi, Bentolhoda, Karpisheh, Vahid, Masjedi, Ali, Abolhasani, Shiva, Izadi, Sepideh, Bagherifar, Rafieh, Hejazian, Seyyed Sina, Mohammadi, Hamed, Movassaghpour, AliAkbar, Feizi, Abbas Ali Hosseinpour, Hojjat-Farsangi, Mohammad, Jadidi-Niaragh, Farhad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391779/
https://www.ncbi.nlm.nih.gov/pubmed/37528446
http://dx.doi.org/10.1186/s12964-023-01213-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391779/
https://www.ncbi.nlm.nih.gov/pubmed/37528446
http://dx.doi.org/10.1186/s12964-023-01213-1

Ejemplares similares